Login
Arena Pharmaceuticals NASDAQ: ARNA
Arena Pharmaceuticals is driven to deliver novel, transformational medicines with optimized pharmacology and pharmacokinetics to patients. Its investigative drug candidates include olorinab, a peripherally restricted, highly selective, full agonist of the cannabinoid receptor type 2 (CB2) in development for the treatment of visceral pain associated with gastrointestinal (GI) diseases
| Name | Arena Pharmaceuticals |
| Ticker | ARNA |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Cannabinoid Therapeutics |
|
Price
52W Low/High |
66.40
60.48 / 87.71 |
| Momentum | Neutral |
| Market cap | 4.0 B |
| 1Y Total Return |
3.60%
Subpar |
| 1Y Volatility |
41.20%
Above Average |
Arena Pharmaceuticals is driven to deliver novel, transformational medicines with optimized pharmacology and pharmacokinetics to patients. Its investigative drug candidates include olorinab, a peripherally restricted, highly selective, full agonist of the cannabinoid receptor type 2 (CB2) in development for the treatment of visceral pain associated with gastrointestinal (GI) diseases
Details
| Ticker | ARNA |
| Name | Arena Pharmaceuticals |
| ISIN | CA0400451062 |
| CUSIP | 040045106 |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Cannabinoid Therapeutics |
| Country | USA |
| Currency | U.S. Dollar |
| In Index(ices) | NASDAQ Biotechnology Index |
Share as of 6/17/2021
| Close Price | 66.40 |
| 52W Low/High | 60.48 / 87.71 |
| Market cap | 4.0 B |
| 1Y Total Return |
3.60%
Subpar |
| 1Y Volatility |
41.20%
Above Average |
| Beta | 1.13 |
| PE (trailing) | - |
| 12M Dividends | - |
| Last Dividend Date | - |
| Dividend Yield | - |
Fin. Strength
| Net Profit Margin | -742,007.0% |
| Cash from Op. / Cur. Liabilities | -7.98 |
| Diluted Earnings / Share | -7.40 |
| ROE | - |
| ROIC | -53.7% |
| Price / Revenue | 69,638.5 |
| Price / Book | 3.7 |
| Price / CF | -10.5 |
| Current Ratio | 23.6 |
| Cur.Liabilities / Tot.Liabilities | 0.5 |
| Financial Leverage | 0.04 |
| in Mils USD |
rolling-year up to March
|
||||||
|---|---|---|---|---|---|---|---|
| Income Statement | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
| Revenue |
0
|
6
|
817
|
21
|
84
|
11
|
|
| Gross Profit |
0
|
6
|
817
|
21
|
88
|
11
|
|
| R&D |
348
|
265
|
139
|
77
|
61
|
80
|
|
| EBITDA |
-415
|
-315
|
632
|
-91
|
-13
|
-93
|
|
| Operating Income |
-454
|
-346
|
611
|
-102
|
-7
|
-101
|
|
| Net Income exc. Extra |
-
|
-
|
623
|
-
|
-
|
-
|
|
| per Share | |||||||
| Diluted avg Shares |
60
|
50
|
51
|
40
|
24
|
24
|
|
| EPS exc. Extra |
-7.40
|
-6.40
|
12.24
|
-2.96
|
-0.95
|
-4.39
|
|
| Dividend |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Div. Yield (an.) |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Balance Sheet | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
| Total Assets |
1,184
|
1,090
|
1,330
|
685
|
140
|
241
|
|
| Cash, Eq & Invt ShortTerm |
1,089
|
800
|
1,104
|
629
|
80
|
140
|
|
| Total Current Assets |
1,122
|
830
|
1,126
|
650
|
92
|
160
|
|
| Total Non-Current Assets |
62
|
260
|
204
|
36
|
47
|
81
|
|
| Intangibles |
0
|
0
|
0
|
0
|
2
|
8
|
|
| Total Liabilities |
98
|
101
|
87
|
101
|
113
|
204
|
|
| Total Current Liabilities |
48
|
44
|
32
|
43
|
50
|
50
|
|
| Long Term Debt |
50
|
57
|
55
|
59
|
63
|
153
|
|
| Shareholder equity |
1,086
|
988
|
1,243
|
584
|
27
|
38
|
|
| Cash Flow | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
| Cash from Operations |
-379
|
-263
|
635
|
-80
|
-60
|
-93
|
|
| Depreciation |
4
|
3
|
4
|
4
|
4
|
5
|
|
| Cash from Investing |
167
|
-284
|
-428
|
-110
|
-1
|
-7
|
|
| Capex |
0
|
4
|
1
|
0
|
0
|
2
|
|
| Cash from Financing |
455
|
10
|
3
|
625
|
3
|
-1
|
|
| Stock Issued |
459
|
13
|
7
|
629
|
6
|
2
|
|
| Debt (LT) Issued |
-4
|
-3
|
-4
|
-4
|
-3
|
-3
|
|
| Free Cash Flow |
-457
|
-751
|
586
|
-206
|
-22
|
-104
|
|
| Ratios | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
| Net Profit Margin |
-
|
-
|
76.2%
|
-
|
-
|
-
|
|
| NCFO / Op.Income |
-
|
-
|
104.0%
|
-
|
-
|
-
|
|
| Current Ratio |
23.6
|
18.7
|
35.5
|
15.3
|
1.9
|
3.2
|
|
| Financial Leverage D/E |
0.04
|
0.05
|
0.04
|
0.10
|
2.42
|
1.80
|
|
| Return on Capital Avg |
-53.7%
|
-44.6%
|
180.2%
|
-138.9%
|
-53.8%
|
-200.2%
|
|
| Return on Shareholder Equity |
-
|
-
|
68.1%
|
-
|
-
|
-
|
|
Fundamentals
No documents are available for the moment, please check back soon, or save the asset to be notified when documents are available